Dyne Therapeutics (DYN) Common Equity (2019 - 2026)

Dyne Therapeutics' Common Equity history runs 8 years deep, the most recent figure standing at $865.1 million for Q1 2026.

• In Q1 2026, Common Equity rose 29.31% year-over-year to $865.1 million; the TTM figure through Mar 2026 stood at $865.1 million (up 29.31% YoY), while the FY2025 annual figure was $972.1 million, up 54.35% from the prior year.
• Common Equity was $865.1 million for Q1 2026 at Dyne Therapeutics, down from $972.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $972.1 million in Q4 2025 to a low of $91.3 million in Q4 2023.
• Historically, Common Equity has averaged $480.9 million across 5 years, with a median of $478.1 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Common Equity tumbled 63.83% in 2023, then surged 589.92% in 2024.
• A 5-year view of Common Equity shows it stood at $252.4 million in 2022, then sank by 63.83% to $91.3 million in 2023, then soared by 589.92% to $629.8 million in 2024, then surged by 54.35% to $972.1 million in 2025, then slipped by 11.01% to $865.1 million in 2026.
• The last three Common Equity figures came in at $865.1 million (Q1 2026), $972.1 million (Q4 2025), and $691.8 million (Q3 2025), per Business Quant data.